New York City-based NYU Langone Health has tapped Vivek Subbiah, MD, as director of two specialty programs at the Perlmutter Cancer Center.
Dr. Subbiah will begin serving as director of the cancer center’s Early Phase Drug Development Program and Rare Cancer Program Nov. 1, according to an Oct. 22 news release from NYU Langone.
He joins NYU Langone from Palo Alto, Calif.-based Stanford Medicine, where he served as executive medical director for novel therapies and clinical trial network development; associate director for drug development and precision oncology at the Stanford Cancer Institute; and the Jeffrey and Christina Bird Endowed Chair at Stanford University School of Medicine.
Dr. Subbiah previously served as center medical director of the early-phase clinical trials program at Houston-based University of Texas MD Anderson Cancer Center and executive medical director of medical oncology research for the MD Anderson Cancer Network, as well as chief of early-phase drug development at Nashville, Tenn.-based Sarah Cannon Research Institute.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
